Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- Cardiologists grapple with potential CV risks posed by e-cigarettes
-
- FDA approves Fragmin, first anticoagulant for children
- Treatments for cardiomyopathy from transthyretin-mediated amyloidosis approved by FDA
- AHA: Despite improvements in HIV treatment, CVD risk elevated
- Familial hypercholesterolemia screening in blood donations may diagnose more patients
- Frequent energy drink consumption may be harmful to heart
- Neladenoson not beneficial in HFpEF
- End-stage renal disease increases risk for mortality, bleeding after TAVR
- Alteplase effective up to 9 hours after ischemic stroke
-
- Bempedoic acid with PCSK9 inhibitor safely reduces lipids
- Cardiogenic shock protocol improves survival
- Components of Mediterranean diet can be individualized for goal attainment
- Exercise should be emphasized in patients with dyslipidemia
- FFR changes treatment plan after angiography in more than 30% of cases
- Next Gen Innovator wins award for paper on His bundle pacing
- ORION-3: Inclisiran safely reduces LDL by more than 50%
- Price reductions of PCSK9 inhibitors contributed to greater cost-effectiveness
-
- Pulsed field ablation safe for paroxysmal AF
- REAFFIRM: Rotor ablation similar to conventional ablation in persistent AF
- ULTIMATE: IVUS guidance may mitigate poor PCI outcomes in chronic kidney disease
- Out of the loop: Augmenting diuresis with SGLT2 inhibitors in HF Megan Valente, PharmD, BCACP; Kathleen D. Faulkenberg, PharmD, BCPS; Sarah A. Spinler, PharmD, FCCP, FAHA, FASHP, AACC, BCPS (AQ Cardiology)
- CAPTURE
- CHOICE
- COMMENCE
- EXPAND
-
- ImpACT24-B
- ORION-3
- RACE 7 ACWAS
- REAFFIRM